Viridian Therapeutics Inc
Change company Symbol lookup
Select an option...
VRDN Viridian Therapeutics Inc
NIO NIO Inc
EWA iShares MSCI Australia ETF
WDAY Workday Inc
BNOX Bionomics Ltd
NRDY Nerdy Inc
KEY KeyCorp
AMPX Amprius Technologies Inc
TPC Tutor Perini Corp
LTRN Lantern Pharma Inc
Go

Health Care : Biotechnology | Small Cap Blend

Viridian Therapeutics, Inc. is a biotechnology company focused on discovering and developing medicines for serious and rare diseases. The Company is engaged in developing three product candidates, VRDN-001, VRDN-002, and VRDN-003, that is developed for intravenous (IV) or subcutaneous administration to treat patients who suffer from thyroid eye disease (TED). Its lead product candidate, VRDN-001, is a differentiated humanized monoclonal antibody targeting insulin-like growth factor-1 receptor (IGF-1R), a clinically and commercially validated target for the TED. It has initiated a Phase I/II clinical trial of VRDN-001. Its second product candidate, VRDN-002, is a distinct IGF-1R antibody that incorporates half-life extension technology, and is designed to support administration as a convenient, low volume, subcutaneous injection to treat patients who suffer from TED. VRDN-003 is an anti-IGF-1R monoclonal antibody with the same amino acid sequence as VRDN-001.

Closing Price: $15.16

Day's Change: -0.21 (-1.37%)

Bid: --

Ask: --

B/A Size: --

Day's High: 15.55

Day's Low: 14.87

Volume (Below Average) Volume: 430,107 10-day average volume: 518,446: 430,107

September 27, 2023
1:02 pm ET	INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Viridian Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm LOS ANGELES, CA / ACCESSWIRE / September 27, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Viridian Therapeutics, Inc. ("Viridian" or "the Company")...(Accesswire)
September 25, 2023
8:00 am ET	Viridian Appoints Sarah Gheuens, M.D., Ph.D., to its Board of Directors Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the appointment of Sarah Gheuens, M.D., Ph.D., to its...(BusinessWire)
September 07, 2023
8:01 am ET	Viridian Therapeutics Announces Presentations at Multiple Medical Meetings in September Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that multiple abstracts featuring clinical and preclinical...(BusinessWire)
August 25, 2023
5:01 am ET	INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Viridian Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm LOS ANGELES, CA / ACCESSWIRE / August 25, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Viridian Therapeutics, Inc. ("Viridian" or "the Company")...(Accesswire)
August 08, 2023
4:30 pm ET	Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Misses Revenue Estimates Viridian Therapeutics, Inc. (VRDN) delivered earnings and revenue surprises of -0.79% and 78.18%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?(Zacks)
4:01 pm ET	Viridian Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update --- THRIVE Phase 3 trial in patients with active TED amended to reflect Viridian's confidence in 5-infusion treatment regimen and key stakeholder feedback on evolving TED treatment paradigm - --- THRIVE-2 Phase 3 trial in patients with chronic TED...(BusinessWire)
August 04, 2023
4:01 pm ET	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the "Company" or "Viridian"), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the...(BusinessWire)
August 03, 2023
6:02 am ET	INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Viridian Therapeutics, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm LOS ANGELES, CA / ACCESSWIRE / August 3, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Viridian Therapeutics, Inc. ("Viridian" or "the Company")...(Accesswire)
July 18, 2023
6:01 am ET	INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Viridian Therapeutics, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm LOS ANGELES, CA / ACCESSWIRE / July 18, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Viridian Therapeutics, Inc. ("Viridian" or "the Company")...(Accesswire)
July 17, 2023
7:01 am ET	INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Viridian Therapeutics, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm LOS ANGELES, CA / ACCESSWIRE / July 17, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Viridian Therapeutics, Inc. ("Viridian" or "the Company")...(Accesswire)
July 14, 2023
6:01 am ET	SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Viridian Therapeutics, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm LOS ANGELES, CA / ACCESSWIRE / July 14, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Viridian Therapeutics, Inc. ("Viridian" or "the Company")...(Accesswire)
July 11, 2023
8:36 pm ET	INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Viridian Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm Los Angeles, California--(Newsfile Corp. - July 11, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Viridian Therapeutics, Inc. ("Viridian" or "the...(Newsfile)
7:02 am ET	INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Viridian Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm LOS ANGELES, CA / ACCESSWIRE / July 11, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Viridian Therapeutics, Inc. ("Viridian" or "the Company")...(Accesswire)
July 10, 2023
8:35 pm ET	INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Viridian Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm Los Angeles, California--(Newsfile Corp. - July 10, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Viridian Therapeutics, Inc. ("Viridian" or "the...(Newsfile)
4:55 pm ET	Viridian stock falls more than 15% after drug study update Shares of Viridian Therapeutics Inc. (VRDN) fell in the extended session Monday after the biotech drug maker said it was making changes to its study design for a chronic thyroid eye disease therapy. Viridian shares fell more than 17% after...(MarketWatch)
4:01 pm ET	Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED) --- Ongoing THRIVE Phase 3 trial in patients with active TED amended to reflect Viridian's confidence in 5-dose regimen and key stakeholder feedback on evolving TED treatment paradigm - --- THRIVE-2 Phase 3 trial in patients with chronic TED...(BusinessWire)
July 06, 2023
4:05 pm ET	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the "Company" or "Viridian"), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the...(BusinessWire)

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for varies.

Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and